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Abstract 
Background: The high incidence and mortality rate of malaria remains a serious burden for many developing 
countries, and a vaccine that induces durable and highly effective immune responses is, therefore, desirable. An 
earlier analysis of the stage-specific in vitro efficacy of a malaria vaccine candidate cocktail (VAMAX) considered the 
general properties of complex multi-component, multi-stage combination vaccines in rabbit immunization experi-
ments using a hyper-immunization protocol featuring six consecutive boosts and a strong, lipopolysaccharide-based 
adjuvant. This follow-up study investigates the effect of antigen dose on the in vitro efficacy of the malaria vaccine 
cocktail using a conventional vaccination scheme (one prime and two boosts) and a human-compatible adjuvant 
(Alhydrogel®).
Results: IgG purified from rabbits immunized with 0.1, 1, 10 or 50 µg doses of the VAMAX vaccine candidate cock-
tail was analysed for total IgG and antigen-cocktail-specific titers. An increase in cocktail-specific titers was observed 
between 0.1 and 1 µg and between 10 and 50 µg, whereas no significant difference in titers was observed between 
1 and 10 µg. Antigen component-specific antibody titers and stage-specific in vitro efficacy assays were performed 
with pooled IgG from animals immunized with 1 and 50 µg of the VAMAX cocktail. Here, the component-specific anti-
body levels showed clear dose dependency whereas the determined stage-specific in vitro IC50 values (as a correlate 
of efficacy) were only dependent on the titer amounts of stage-specific antibodies.
Conclusions: The stage-specific in vitro efficacy of the VAMAX cocktail strongly correlates with the corresponding 
antigen-specific titers, which for their part depend on the antigen dose, but there is no indication that the dose has 
an effect on the in vitro efficacy of the induced antibodies. A comparison of these results with those obtained in the 
previous hyper-immunization study (where higher levels of antigen-specific IgG were observed) suggests that there 
is a significant need to induce an immune response matching efficacy requirements, especially for a PfAMA1-based 
blood stage vaccine, by using higher doses, better adjuvants and/or better formulations.
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Background
Malaria remains a major challenge for the healthcare 
systems and economies of many developing countries, 
especially in sub-Saharan Africa [1] and an efficient vac-
cine would help to address the problems associated with 
constantly evolving drug resistance of the parasite, Plas-
modium falciparum [2]. Several strategies can be chosen 
in the context of malaria vaccine development. Vaccines 
can target “lower hanging fruits” such as the prevention 
or reduction of clinical manifestation, pregnancy-asso-
ciated malaria, and malaria transmission, or they can 
aim for the “holy grail” of sustained strain-transcending 
sterile protection. While the GSK vaccine Mosquirix®, 
based on circumsporozoite protein (PfCSP) [3–5], exclu-
sively targets the pre-erythrocytic stage of P. falciparum 
to prevent the establishment of the parasite within the 
liver, other approaches focus on blood-stage antigens 
that can be found on the surface of merozoites, to induce 
immune responses that block the invasion of red blood 
cells and thereby prevent or reduce clinical episodes. A 
vaccine that reduces the blood-stage parasite load may 
also reduce transmission. In addition to PfMSP1 and 
fragments thereof [6, 7], PfMSP2 [8] and PfMSP3 [9, 10], 
the apical membrane antigen PfAMA1 [11, 12] has been 
proposed as a promising blood-stage vaccine candidate. 
This molecule is highly polymorphic, so allele-specific 
immune responses show moderate or even low efficacy 
against heterologous strains of P. falciparum. The allelic 
diversity of PfAMA1 has been addressed by the design 
of three artificial, diversity-covering variants (DiCo1-
3) [13] or by combining three [14], four [15], six [16] or 
seven [17] different PfAMA1 alleles. In the field of trans-
mission-blocking vaccines (TBVs), a zygote and ooki-
nete surface antigen remains the leading candidate [18] 
and is undergoing clinical investigation [19]. The authors 
of the current article previously designed and analysed 
the stage-specific in  vitro efficacy of a malaria antigen 
cocktail [20] comprising three recombinant fusion pro-
teins combining the three PfAMA1_DiCo variants each 
with Pfs25, and PfMSP1-19 (VAMAX1), PfCSP_TSR 
(VAMAX2) or PfCelTOS (VAMAX4). The latter work 
demonstrated the ability of the multi-component vac-
cine cocktail (VAMAX1, 2 and 4) featuring antigens from 
different stages of the P. falciparum life cycle to elicit 
parasite growth-inhibitory responses against the pre-
erythrocytic stage, the blood stage and the sexual stage. 
However, the authors observed the proteolytic degrada-
tion of VAMAX4, leading to the loss of the C-terminal 
fusion partner PfCelTOS. Modified variants of VAMAX4 
were, therefore, investigated, and in VAMAX6 PfCel-
TOS was replaced with a promising epitope (Q5A) [21] 
derived from the blood-stage antigen PfRH5 [22]. In con-
trast to the immunization experiments with the initial 
cocktail (VAMAX1, 2 and 4) which featured a hyper-
immunization regime (high 200  µg prime dose and five 
boosts of 100  µg), the work described herein investi-
gated the dose-dependency of immune responses and 
stage-specific in  vitro efficacy for the modified cocktail 
(VAMAX1, 2 and 6) using a human-compatible adjuvant 
(Alhydrogel®) and a one prime/two boosts vaccination 
regime. Additionally, the authors sought to confirm the 
observed correlation between antigen abundance within 
the improved VAMAX cocktail and the proportions of 
the corresponding antigen-specific antibodies found in 
the rabbit immune IgG fraction.
Methods
Construct design and cloning
The design and cloning of constructs VAMAXl and 
VAMAX2 and selection of recombinant Pichia pastoris 
clones was previously described [20]. VAMAX6 compris-
ing PfDiCo3, Pfs25 and the epitope of blood-stage antigen 
RH5-specific, parasite-inhibitory monoclonal antibody 
Q5A (amino acids 198–213, GeneID PF3D7_0424100) 
was obtained as a Pichia pastoris codon-optimized 
synthetic gene from GeneArt (Invitrogen, Carlsbad, 
CA) (Fig.  1a). The construct was inserted as previously 
described [20] into a Pichia pastoris expression vector 
containing the methanol inducible AOX1 promoter and 
terminator to control transgene expression. Cloning was 
confirmed by DNA sequencing. The constructs did not 
contain any potential N-glycosylation motif which occur 
in the natural sequences of PfAMA1, and Pfs25. For 
details on the used knock-out mutations refer to the fol-
lowing publications [23, 24].
Transformation and screening of Pichia pastoris
The transformation, cultivation and screening of Pichia 
pastoris strain CBS704 was carried out as previously 
described [25].
Fed‑batch fermentation and purification of the antigens
The pre-cultures were prepared and the cultivations 
were carried out as previously described [20, 25] with 
minor changes. The number of fermentation phases was 
reduced to two, so the process consisted only of a batch 
and an immediate induction phase. For the latter phase, 
the temperature was lowered to 25 °C and the methanol 
concentration was kept constant at 0.25  % (v/v) by the 
use of an ALKOSENS probe combined with an ACETO-
MAT NII controller (Heinrich Frings GmbH & Co. KG, 
Bonn, Germany). During induction, the dissolved oxy-
gen tension continuously dropped to 0  % as the stirrer 
speed reached a maximum of 600 rpm. When a total of 
2.7 kg methanol was added, the pH was adjusted to 7.0 
followed by the harvest and centrifugation of the broth 
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(9000×g, 20 min, 4 °C). The culture supernatant was col-
lected for immediate processing or for storage at–20 °C. 
Antigens were purified by immobilized metal ion affinity 
chromatography (IMAC) using Chelating Sepharose Fast 
Flow (GE Healthcare Life Sciences, Little Chalfont, UK) 
as a capture step (the N-terminal pro-peptide of PfAMA1 
included in all three constructs binds to copper-charged 
chelating Sepharose Fast Flow resin) followed by buffer 
exchange using a HiPrep 26/10 column (GE Health-
care) and anion exchange (AEX) chromatography using 
Q Sepharose HP (GE Healthcare). Finally, samples were 
concentrated with a Centriprep YM-10 concentra-
tor (Merck, Darmstadt, Germany) and polished by size 
exclusion chromatography (SEC) on a Sephacryl S-100 
HR 16/60 column (GE Healthcare).
LDS‑PAGE and immunoblot analysis
Purified VAMAX1, VAMAX2 and VAMAX6 were frac-
tionated separately under non-reducing conditions on 
4–12  % (w/v) polyacrylamide gradient gels (NuPage, 
Thermo Fisher Scientific, Waltham, MA, USA) and 
either stained with Coomassie Brilliant Blue (Fig. 1b) or 
transferred onto a nitrocellulose membrane (Whatman, 
GE Healthcare) for immunoblot analysis as previously 
described [26]. After blocking with 5  % (w/v) skimmed 
milk dissolved in phosphate buffered saline (PBS), 
the VAMAX1, 2 and 6 proteins were probed with the 
Pfs25-specifc monoclonal antibody mAb4B7 (obtained 
by MR4) as well as the plant-derived chimeric variant 
PfAMA1-specific mAb4G2 (provided by Stefan Menzel, 
Fraunhofer IME, Aachen, Germany) (Fig. 1c). Addition-
ally, mAb6.75, a PfCSP_TSR-specific murine monoclo-
nal antibody generated by Christoph Kühn (Fraunhofer 
IME), was used specifically to detect the C-terminal 
PfCSP of VAMAX1 and the murine mAb5.2 (obtained 
by MR4) enabled the specific detection of the C-terminal 
PfMsp1_19 of VAMAX2. All primary antibodies were 
Fig. 1 Antigen design, LDS-PAGE and immunoblot blot analysis of 
VAMAX 1, VAMAX 2 and VAMAX 6 expression. a Schematic rep-
resentation of the VAMAX 1, VAMAX 2 and VAMAX 6 fusion anti-
gens. DiCo1–3 diversity covering variants of PfAMA1 (red); Pfs25 P. 
falciparum 3D7 sexual-stage surface antigen Pfs25 (blue); PfCSP_TSR 
thrombospondin-related region from P. falciparum 3D7 circumsporo-
zoite protein PfCSP (gray); PfMSP1_19 C-terminal 19 kDa fragment 
of merozoite surface protein 1 (PfMSP1_19) from P. falciparum strain 
FUP (pink); PfRH5_Q5A Short amino acid stretch of the reticulocyte-
binding protein homologue 5 (PfRH5) of P. falciparum 3D7, epitope 
of the invasion inhibitory antibody mAb Q5A. b LDS-PAGE analysis 
under non-reducing conditions of VAMAX 1 (V1), VAMAX 2 (V2) and 
VAMAX6 (V 6) after purification (3.4 µg of each VAMAX fusion protein 
per lane). c Immunoblot analysis under non-reducing conditions 
of purified VAMAX fusion proteins (V1, V2 and V6): 1.3 µg of each 
VAMAX fusion protein was loaded and the fusion proteins (V1, V2 and 
V6) were detected either with the plant-derived chimeric PfAMA1-
specific mAb4G2 (left panel) or the murine Pfs25-specific mAb4B7 
(MRA28, MR4, ATCC) (right panel). d Immunoblot analysis under 
non-reducing conditions. Left panel: Purified VAMAX 1 (V1, 1.3 µg) 
was detected using a PfCSP_TSR domain-specific murine monoclonal 
antibody mAb6.75; right panel: Purified VAMAX 2 (V2, 1.3 µg) was 
detected using the PfMSP1_19-specific murine monoclonal antibody 
mAb5.2 (MRA94, MR4, ATCC). e LDS-PAGE (left panel, 3.4 µg) and 
immunoblot analysis (right panel, 1.3 µg) of an equimolar mixture 
of VAMAX 1, VAMAX 2 and VAMAX 6 (VM). Immunoblot analysis was 
performed under non reducing conditions and the equimolar VAMAX 
mixture was detected with the plant-derived chimeric PfAMA1-
specific mAb4G2. Primary antibodies were detected with alkaline 
phosphatase-labeled goat anti-human or anti-mouse antisera. M: 
PageRuler™ Pre-stained protein ladder (Fermentas)
▸
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used at a concentration of 1 µg/ml (Fig. 1d). The second-
ary antibody was an alkaline phosphatase-labeled goat 
anti-mouse H +  L or alkaline phosphatase-labeled goat 
anti-human Fc (both from Jackson Immunoresearch, 
West Grove, PA, USA).
Mass spectrometry (MS)
Proteins fixed in polyacrylamide gels were reduced, 
alkylated and digested with trypsin (Promega, Man-
nheim, Germany) as previously described [27]. The 
resulting peptides were analysed by nanoHPLC (Ulti-
Mate 3000 HPLC system, LC Packing, Dionex, Idstein, 
Germany) coupled to an amaZon ETD MS ion trap spec-
trometer (Bruker Daltonics, Bremen, Germany) using 
ESI nano sprayer. MS/MS spectra were searched for 
peptides of interest using the local search engine Mascot 
Search v2.3.01 (Matrix Science Ltd, London, UK). Spe-
cific information on the MS measurements was previ-
ously reported [20].
Antigen formulation
Each purified VAMAX fusion protein (VAMAX 1, 
VAMAX 2 and VAMAX 6) was dialyzed against the for-
mulation buffer (2.4  mM NaH2PO4, 2.6  mM K2HPO4, 
0.125  mM Na2EDTA, 0.27  M D(-)mannitol, pH 6.8) 
(slightly modified from [28]). An equimolar VAMAX mix-
ture was prepared and filter sterilized using a Pall Acro-
disc 32 mm Supor filter (pore size 0.2 µm). The equimolar 
VAMAX mixture was adjusted to 200 µg/ml (50 µg vac-
cine dose), 40 µg/ml (10 µg vaccine dose), 4 µg/ml (1 µg 
vaccine dose) or 0.4  µg/ml (0.1  µg vaccine dose) with 
filter-sterilized formulation buffer and 1.7  ml of each 
VAMAX mixture was filled into clear glass injection vials 
(2 ml, 13-mm crimp neck) and lyophilized. The vials were 
sealed with rubber stoppers and aluminum crimp seals. 
One vial was used per immunization time point and dose. 
For the alum formulation, a pre-dilution of GMP-grade 
Alhydrogel® was prepared by mixing 3.2  ml Alhydro-
gel® with 6.8 ml saline under sterile conditions. The Aly-
drogel® pre-dilution was mixed by gentle agitation and 
allowed to equilibrate for 60 min at 4 °C. A lyophilized vial 
was reconstituted with 1.7 ml saline under sterile condi-
tions and four aliquots of 280 µl were transferred to sterile 
1.5-ml reaction tubes. Samples were stored at 4  °C, and 
280 µl of the Alhydrogel® pre-dilution was added to each 
vial to obtain the final immunization dose, resulting in 
0.8 mg Al3+ per 500 µL immunization dose. The adsorp-
tion of the VAMAX mixture to Alhydrogel® under formu-
lation conditions was determined to be >95 %.
Rabbit immunization, titer determination
Rabbits were housed, immunized and sampled by Bio-
genes GmbH (Berlin, Germany), according to national 
animal welfare regulations. After equilibration of the 
vials for 60 min at 4 °C, each rabbit was immunized with 
an injection dose of 500 µl. For each dose (0.1, 1, 10 and 
50 µg), four rabbits were immunized on days 0 (prime), 
28 (boost 1) and 56 (boost 2). Serum samples were taken 
on days 0 (pre-immune) and 70 (final bleed). Titer deter-
mination was carried out as previously described by 
direct ELISA using the VAMAX antigen cocktail to coat 
the ELISA plates (100 ng/well) [26].
Antibody purification
Total IgG was purified by conventional Protein A affin-
ity chromatography using 40 ml immune serum (day 70) 
from rabbits immunized with the 1-µg dose and 20  ml 
immune serum from rabbits immunized with the 50-µg 
dose. Bound antibodies were eluted with 100  mM gly-
cine (pH 3.0) and directly neutralized by adding 10  % 
(v/v) 1 M Tris–HCl (pH 8.0). The elution fractions were 
concentrated to 2.5 ml using VIVASPIN 15R centrifugal 
concentration devices with a molecular weight cut off of 
30 kDa (Sartorius, Göttingen, Germany), and exchanged 
against 5  mM phosphate buffer (pH 7.5) using dispos-
able PD10 columns (GE Healthcare). After lyophilization, 
the samples were reconstituted in 600  µl PBS and filter 
sterilized (pore size 0.2 µm). Antibody integrity and the 
total IgG concentration were determined by analytical 
gel filtration as previously described [29]. The final IgG 
preparations were used for calibration-free concentration 
analysis (CFCA) and all subsequent in  vitro inhibition 
assays.
Calibration‑free concentration analysis
The antigen-specific antibody concentrations were meas-
ured in the purified antibody preparations by CFCA [30, 
31] using a Biacore T200 instrument. The purified anti-
gens comprised PfAMA1 variants DiCo 1–3 (provided 
by Stephan Hellwig, Fraunhofer IME, with kind permis-
sion from Bart Faber, BPRC, The Netherlands), PfCSP_
TSR (in the context of CCT, a fusion protein containing 
PfCSP_TSR, PfCelTOS and PfTRAP_TSR [32]), Pfs25 
(in the context of F0, a fusion protein containing Pfs25gk 
and Pfs230_C0, [24]) and PfMSP1_19 (in the context of 
a tetravalent PfMsp1-19 fusion protein, provided by 
Güven Edgü, Fraunhofer IME). The antigens were sepa-
rately covalently coupled to CM5-S-Series sensor chips 
by standard EDC-NHS chemistry as previously reported 
[26]. To match the assay specifications in terms of the ini-
tial binding rates at 5 µl/min, purified rabbit immune IgG 
was used at a concentration of 20–100  µg/ml as deter-
mined by test injections. Initial binding rates at 5, 30 and 
100  µl/min were used to calculate antigen-specific IgG 
concentrations using the CFCA tool in the Biacore T200 
evaluation software.
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Assays
Sporozoite gliding motility assay
Plasmodium falciparum NF54 sporozoites were isolated 
and used in an adapted sporozoite gliding motility (SGM) 
assay [33]. Each triplicate assay required 10,000 sporozo-
ites per well in a 96-well glass bottom black plate. After 
90 min incubation at 37 °C, 98 % relative humidity, 93 % 
(v/v) N2, 4  % (v/v) CO2 and 3  % (v/v) O2, gliding trails 
were washed and stained with biotinylated anti-CSP 
monoclonal antibody 3SP2 followed by AlexaFluor594-
labeled streptavidin (Invitrogen). An automated high-
content microscope (Leica) was used to capture nine 
images per well at 1000× magnification. Images were 
automatically processed with FIJI imaging software, as 
described elsewhere (Bolscher et al., pers. comm.).
Sporozoite invasion and liver stage development assay
The sporozoite invasion and liver stage development 
(SILSD) assay [29] was adapted as follows. Cryopre-
served human hepatocytes (Tebu-Bio) were thawed and 
cultured in a 96-well clear bottom black plate (BD Fal-
con) for 2  days according to manufacturer’s protocol. 
Per well, 50,000 Pf NF54 sporozoites were pre-incubated 
with purified rabbit IgG samples for 30 min on ice, after 
which the mixture was transferred onto the hepatocytes. 
Samples were tested in triplicate and the medium was 
refreshed daily according to the manufacturer’s pro-
tocol. On day 6 after sporozoite invasion, hepatocytes 
were washed and fixed with 4 % (v/v) paraformaldehyde. 
Vehicle and 3SP2 control wells were stained with rab-
bit anti-PfHSP70, followed by AlexaFluor594-labeled 
goat anti-rabbit IgG and 4′,6-diamidino-2- phenylindole 
(DAPI). Vehicle and rabbit IgG samples were stained with 
a pool of mouse monoclonal antibodies directed against 
PfBip (binding protein, a marker of the endoplasmic 
reticulum), PfEXP-1 (exported antigen AG 5.1), PfHSP70 
(heat shock protein 70) and PfMSP1 (merozoite-specific 
protein 1) followed by AlexaFluor488-labeled chicken 
anti-mouse IgG and DAPI. To determine the number of 
positively-stained (infected) hepatocytes, an automated 
high-content microscope (Leica) was used to capture 
25 images per well at 100× magnification. Images were 
automatically processed with FUJI imaging software, as 
described elsewhere (Bolscher et al., pers. comm.).
In vitro growth inhibition assay
The ability of purified polyclonal rabbit IgGs to inhibit 
the growth of P. falciparum strains 3D7, 7G8 and V1-S 
(obtained through the MR4) was determined using 
growth inhibition assays (GIAs) as previously described 
[34]. Reversal of growth inhibition assays were carried 
out as previously described [29].
Standard membrane feeding assay
The standard membrane feeding assay (SMFA) [35] was 
adapted as follows. The diluted rabbit IgG sample (36 μl) 
was mixed with 300  μl PfNF54:HSP70:GFP:luc gameto-
cyte culture adjusted to a final haematocrit of 44.7 % red 
blood cells in 44.6  % human serum-containing active 
complement. The mixture was fed to Anopheles stephensi 
mosquitoes. After 8  days, the mosquitoes were frozen 
at –20 °C and the next day 24 mosquitoes per cage were 
analysed for luciferase expression as a measure for oocyst 
intensities [36]. As controls, 24 uninfected mosquitoes 
were analysed to determine background luminescence 
levels.
Statistics
The antibody titers determined by CFCA were averaged 
(n = 4) for each combination of antibody type (VAMAX 
mix titer, total IgG titer, domain-specific titers) and sam-
ple group [antigen dose, pre-immune serum (P) and 
immune serum (I)] and the normal distribution of the 
data in each of these sample sets was tested using the 
Kolmogorow–Smirnow test (a  =  0.05) [37]. The cor-
rected standard deviation of each sample set was used to 
calculate its variance. Variances were compared using a 
pairwise F-test between sample groups for each antibody 
type (a = 0.05). If differences between the variances were 
not significant and the data points were normally distrib-
uted, a two-sided t test (a = 0.05) was used to identify sig-
nificant differences between the antibody titers of sample 
set pairs. In case multiple group comparisons were made, 
Šídák’s multiple comparisons post hoc test was used fol-
lowing analysis of variance (ANOVA). For the VAMAX 
mix titers, the data were normalized by log-transforma-
tion for analysis. The association between the relative 
proportion of component-specific IgG and the relative 
proportion of molecular weight calculated for the com-
ponents was analysed by calculating the Spearman’s rank 
correlation coefficient. The IC50-values were estimated by 
non-linear regression using the following model: 
Ethics approval and consent to participate
The human cells used in this study were provided by 
Human HepCell (Paris, France). The company obtained 
the permission, issued by the French Ministry of Edu-
cation and Research Ethical Commitee (Decision n° 
AC 2011-1308 de la Cellule Bioéthique de la Direction 
Générale pour la Recherche et l´Innovation du novem-
bre 2011) to provide such samples for research use. The 
donors were informed by their surgeon that the tis-
sues collected during the surgery could be used for 
research purposes only and that they get no financial 
Y = 100/(1+ 10∧(LogIC50 − X))
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compensation for this donation. For each donor, a con-
sent of non-opposition is signed.
Rabbits were housed, immunized and sampled by Bio-
genes GmbH (Berlin, Germany), according to national 
animal welfare regulations. The animal facilities and pro-
tocols were reviewed and approved by: Landesamt für 
Landwirtschaft, Lebensmittelsicherheit und Fischerei 
MecklenburgVorpommern (LALLF M-V) (Approval No: 
7221.3-2-030-13). To isolate the blood after immuniza-
tion according to national regulations the animals were 
anesthetized using Ventranquil, stunned using a captive 
bolt device and exsanguinated by throat cut.
Results
Production of the antigen cocktail
Recombinant Pichia pastoris cultures individually 
transformed with the three expression constructs 
(VAMAX 1, 2 and 6, see Fig.  1a) were used for fed-
batch fermentation (15-L scale). After purification by 
IMAC and SEC, the purity and integrity of the recom-
binant proteins was analysed by LDS-PAGE followed 
by Coomassie staining, immunoblotting and analyti-
cal SEC. Monoclonal antibodies were available for the 
specific detection of each protein domain within the 
three VAMAX fusion proteins except the PfRH5 Q5A 
epitope. The proteins were obtained at high purity 
(>95  % determined by analytical SEC) the apparent 
molecular masses agreed with the calculated values 
of 87,592  Da for VAMAX 1 (measured 87,463  Da), 
89,906  Da for VAMAX 2 (measured 90,312  Da) and 
80,864  Da for VAMAX 6 (measured 80,813  Da) 
(Table 1), there was no indication of relevant amounts 
of degradation products, and the specific monoclo-
nal antibodies detected the corresponding antigen 
domains (Fig. 1b–e). The yields after purification were 
10, 13 and 4  µg/ml (calculated after purification and 
given as µg fusion protein/ml culture supernatant) for 
VAMAX 1, VAMAX 2 and VAMAX 6, respectively. 
MALDI-TOF–MS was used to determine the identity 
and integrity of the three recombinant proteins by ana-
lysing the tryptic fragments and calculating the total 
mass. In accordance with the immunoblot data, tryp-
tic fragments representing each of the protein domains 
were identified. Together with the total mass analysis 
(Table 1), where approximately the expected molecular 
masses were observed for the three recombinant fusion 
proteins (−0.2 % for VAMAX 1, +0.4 % for VAMAX 2 
and −0.1 % for VAMAX 6) these results confirmed the 
presence of fully intact fusion proteins.
Immunization, determination of titers and total IgG levels
Immune sera from rabbits immunized with the different 
doses of the VAMAX 1, 2 and 6 cocktail were used for the 
determination of cocktail-specific titers. Figure 2a shows 
the titers of individual animals as well as the geometric 
mean obtained after immunization with the correspond-
ing doses. Comparing the geometric means of the four 
animals per group, a greater than tenfold increase in titer 
(from 3.8 × 104 to 5.6 × 105) was observed between the 
0.1  and 1  µg doses, which was statistically significant. 
Only a marginal difference in titer was observed between 
the 1  and 10  µg antigen doses (from 5.6 to 6.0  ×  105) 
but the titers showed another statistically significant 
increase between the 10 and 50 µg doses (from 6.0 × 105 
to 2.5 × 106). The observed titers led to the selection of 
samples from the 1 and 50 µg doses for pooling (hereafter 
P1 and P50, respectively) and subsequent analysis in the 
stage-specific parasite inhibition assays. Additionally, the 
total IgG in the sera of the animals before (P) and after 
immunization (I) were compared. As shown in Fig.  2b, 
the total IgG levels after immunization were independ-
ent of the antigen dose because there were no statistically 
significant differences between the geometric mean IgG 
levels between immune sera of the different dose groups, 
which all contained total IgG concentrations of ~14 mg/
ml.
Determination antigen‑specific IgG levels
CFCA was used to determine the amounts of antigen-
specific IgG within pools of purified total IgG from 
immune sera in the P1 and P50 dose groups, enabling 
the correlation of inhibition values obtained from stage-
specific in  vitro assays not only with total IgG but also 
with antigen and/or stage-specific IgG concentrations 
(Table  2). The highest concentration of antigen-specific 
IgG was measured for the PfAMA1_DiCo mix, followed 
by Pfs25, PfMSP1-19 and PfCSP_TSR. Q5A-specific 
IgG could not be quantified since no Q5A peptide-spe-
cific reactivity could be detected in rabbit immune IgG 
by ELISA. The values (µg/ml antigen-specific IgG) were 
used to calculate percent values for the specificity of each 
antigen in relation to total IgG (Fig. 3). Here, pronounced 
differences (up to three-fold for the PfAMA1–DiCo 
mix) were observed between the P1 and P50 groups for 
all four antigens. The observed differences between the 
P1 and P50 groups were statistically significant with the 
exception of PfMSP1_19, although even in this case there 
Table 1 Calculated and measured molecular weight of the 
VAMAX variants
Sample Theoretical mass 
[Da]
Measured mass  
[Da]
Discrepancy [%]
VAMAX1 87,592 87,463 −0.2
VAMAX2 89,906 90,312 +0.4
VAMAX6 80,864 80,813 −0.1
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was a slight tendency towards higher concentrations of 
PfMSP1_19-specific antibodies in the P50 group.
In vitro efficacy assays
The in vitro efficacy of the different doses of the VAMAX 
vaccine cocktail were compared using appropriate stage-
specific in  vitro parasite inhibition assays: pre-erythro-
cytic/liver stage (SGM and SILSD assays), blood stage 
(GIAs), and sexual stage (SMFAs). The assays were car-
ried out using purified and pooled immune IgG prepara-
tions from the P1 and P50 dose groups.
Liver stage efficacy
The SGM assay was carried out at concentrations of 9, 
3 and 1  mg/ml total IgG. Inhibition was measured as a 
percentage relative to the concentration of neutral rabbit 
serum and was plotted against total IgG (Fig. 4a) and the 
corresponding PfCSP-specific IgG (Fig. 4b). Because the 
inhibition values did not exceed 50  % even at the high-
est IgG concentration, the IC50 values were estimated for 
total IgG as well as PfCSP-specific IgG and summarized 
in Table  3. An inhibition value of ±50  % was observed 
for the highest total IgG concentration in the case of the 
Fig. 2 Determination of the VAMAX-mix specific titer and quantification of total IgG concentration in serum samples. a The VAMAX-mix-specific 
titer after immunization of four rabbits in each antigen group (0.1, 1, 10 and 50 µg of VAMAX-mix formulated with Alhydrogel® using a one prime/
two boost immunization schedule) were assessed by direct coating ELISA using the VAMAX-mix as the coating antigen. b Total IgG concentration 
in the pre-immune (P) and immune serum (I) collected on day 70 was quantified by surface plasmon resonance spectroscopy using a protein A 
capture chip and a quantified rabbit IgG reference for the generation of a standard curve. Gray: 0.1 µg antigen dose; blue: 1 µg antigen dose; green: 
10 µg antigen dose; orange: 50 µg antigen dose; square: Rabbit 1 (R1); circle: Rabbit (R2); upward triangle: Rabbit 3 (R3); downward triangle: Rab-
bit (R4); black horizontal line: geometric mean. For detailed statistical analysis refer to “Methods” section. Asterisks indicate a significant difference 
(a = 0.05), whereas “NS” indicates no significant differences
Table 2 Total and component-specific IgG concentrations in the purified rabbit immune IgG preparations













50 R1 148.1 5.290 0.190 2.700 1.100 1.300
50 R2 136.4 3.170 0.130 1.400 0.540 1.100
50 R3 130.9 3.540 0.180 1.900 0.360 1.100
50 R4 127.1 3.160 0.150 2.100 0.380 0.530
1 R1 157.9 1.466 0.026 0.890 0.160 0.390
1 R2 125.6 0.481 0.021 0.180 0.010 0.270
1 R3 160.0 2.040 0.150 1.100 0.190 0.600
1 R4 116.0 2.188 0.083 1.100 0.425 0.580
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P50 sample, whereas only ±20 % inhibition was observed 
at the same total IgG concentration for the P1 sample, 
reflecting the quantitative differences in PfCSP-specific 
IgG between the two dose groups (Fig. 3).
Additionally, the SILSD assay was carried out by com-
bining sporozoites with 9 mg/ml total IgG onto cryopre-
served primary human liver cells. In agreement with the 
SGM assay, different degrees of inhibition were observed 
(±40  % for P50 and ±30  % for P1), which again corre-
lated with the quantitative differences in PfCSP-specific 
antibodies in the total IgG preparations of P1 and P50 
(Fig. 4c).
Blood stage efficacy
Strain-dependent blood-stage-specific efficacy was 
addressed by carrying out GIAs using different P. falcipa-
rum strains (3D7, 7G8 and V1-S) to account for the major 
polymorphisms covered by the three DiCo variants. 
Figure  5a shows the strain-specific dose-dependency of 
growth inhibition for total immune IgG pools P1 and 
P50. The different IC50 values are summarized in Table 3. 
Additionally, a reversal of growth inhibition assay was 
carried out to investigate the contribution of PfAMA1_
DiCo mix-specific IgG to blood stage-specific in  vitro 
efficacy, using the 3D7 reference strain and PfAMA1_
DiCo mix as a competitor. As shown in Fig.  5b the 
growth-inhibitory effect of rabbit immune IgG was com-
pletely neutralized when a mixture of PfAMA1_DiCo was 
used at equal or higher molar concentrations, compared 
to rabbit immune IgG antigen-binding sites. Because 
this finding indicates that the parasite growth-inhibitory 
activity measured in this assay is exclusively mediated 
by PfAMA1_DiCo mix-specific antibodies, it was possi-
ble to estimate IC50 values in relation to the concentra-
tions of PfAMA1_DiCo mix-specific antibodies (Fig. 5c). 
The calculated IC50 values in relation to PfAMA1_DiCo 
mix-specific antibodies as well as total IgG are shown 
in Table 3. No significant differences of IC50 values were 
observed for the PfAMA1_DiCo mix-specific antibodies 
(120–180 µg/ml) or total IgG (8–30 mg/ml) between the 
P50 and P1 dose pools as well as between the different 
parasite strains.
Sexual stage efficacy
The potential transmission-blocking activity of the 
VAMAX 1, 2 and 6 specific rabbit immune IgG was ana-
lysed by SMFA. The transmission-blocking activity of 
sera derived from the P1 and P50 dose pools correlated 
with the concentration of Pfs25-specific IgG (Fig. 6). As 
shown in Table 3, the estimated IC50 did not deviate sig-
nificantly between the P1 and P50 dose pools (1.409 and 
1.049 µg/ml, respectively, for Pfs25-specific IgG).
Discussion
After the predominantly disappointing results achieved 
with many single-component malaria vaccine candidates 
in clinical trials, the concept of combining different P. 
falciparum antigens to improve, immunogenicity, effi-
cacy and strain coverage has received greater attention 
[38, 39]. The authors of this article are following differ-
ent approaches towards the development of a multi-stage 
multi-component malaria vaccine cocktail. In this con-
text, a vaccine cocktail was developed [20] comprising 
three recombinant fusion proteins based on the three 
diversity-covering (DiCo) variants of the P. falcipa-
rum apical membrane antigen PfAMA1 developed by 
Remarque et  al. [13], each featuring Pfs25 fused to the 
C-terminus of the PfAMA1_DiCo variant, and addition-
ally the TSR-domain of PfCSP (VAMAX 1), the 19 kDa 
C-terminal fragment of PfMSP1 (VAMAX 2) or PfCel-
TOS (VAMAX 4). A further approach based on a cocktail 
of VAMAX 1, 2 and 4 used a hyper-immunization proto-
col to induce high immune IgG titers, to generally con-
firm and dissect the multi-stage in  vitro efficacy of the 
Fig. 3 Antigen-specific IgG concentration in the purified total IgG 
fraction. The antigen specific IgG concentration for the correspond-
ing antigen (PfCSP_TSR, PfAMA1_DiCo mix, PfMSP1_19 and Pfs25) 
was quantified in the total IgG fraction purified from the immune 
serum samples collected on day 70 from rabbits receiving the 1 µg 
(P1, blue) and 50 µg antigen dose (P50, orange). The quantification 
was performed using the calibration-free concentration analysis 
module of the Biacore T200 instrument (surface plasmon reso-
nance spectroscopy) and the antigen-specific IgG concentration is 
expressed as a percentage of total IgG. Square: Rabbit 1 (R1); circle: 
Rabbit (R2); upward triangle: Rabbit 3 (R3); downward triangle: Rabbit 
(R4); black horizontal line: geometric mean. For detailed statistical 
analysis refer to the “Methods” section. Asterisks indicate a significant 
difference (a = 0.05), whereas “NS” indicates no significant differences
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fusion antigen cocktail. In the current study, the dose-
dependency of antigen-specific titers and in vitro efficacy 
was investigated based on a more realistic immunization 
scheme and a human-compatible adjuvant. Because pro-
teolytic cleavage of the C-terminal PfCelTOS domain in 
the DiCo3-based VAMAX4 was previously observed, 
a modified variant (VAMAX 6) was used in this study, 
in which PfCelTOS was replaced with the Q5A epitope 
from the blood-stage antigen PfRH5.
All three fusion proteins (VAMAX 1, 2 and 6) were 
produced by Pichia pastoris fed-batch fermentation and 
a purity of >95 % was achieved after IMAC and SEC for 
all three proteins. The observed yields (VAMAX 1 10 µg/
ml, VAMAX 2 13 µg/ml, VAMAX 6 4 µg/ml, calculated 
after purification given as µg fusion protein/ml culture 
supernatant) were within the previously observed range 
for the production and purification of the VAMAX 1, 2 
and four variants [20] but lower than the yields originally 
reported for PfAMA1 (120 µg/ml, after purification) [40]. 
Lower expression levels may result either from intrin-
sic features of the fusion partner, or from the increased 
size of the fusion protein for different PfAMA1_DiCo 
fusion proteins where yield was inversely related to the 
protein size [41]. The integrity and conformation of the 
Fig. 4 Confirmation of pre-erythrocytic stage in vitro efficacy by sporozoite gliding motility (SGM) and sporozoite invasion and liver stage develop-
ment (SILSD) assays. The in vitro efficacy of antibodies induced by VAMAX-mix immunization was assessed by SGM and SILSD assays. Total IgG was 
purified from rabbit immune serum samples collected on day 70 and the total IgG fractions from the corresponding groups (four rabbits per group) 
were pooled (P1: 1 µg antigen dose, blue; P50: 50 µg antigen dose, orange). Data represent means and standard deviations of three experiments. 
a The dose-dependency of sporozoite gliding motility inhibition was investigated for P1 and P50 using 9, 3 and 1 mg/ml total IgG (a) and the 
inhibition was also correlated with the PfCSP_TSR-specific antibody concentration (b). Based on both graphs, the IC50 values for total IgG as well as 
PfCSP_TSR-specific antibodies were calculated and summarized in Table 3. c The inhibition of sporozoite invasion and liver-stage development was 
assessed for P1 and P50 at 9 mg/ml total IgG and the corresponding PfCSP_TSR-specific antibody concentration is illustrated
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recombinant proteins was investigated by LDS-PAGE, 
immunoblot with antigen-domain-specific antibod-
ies, and mass spectrometry, confirming the presence of 
intact, full-size proteins. There was no indication of pro-
teolytic cleavage, previously reported for the VAMAX 
four component in which most of the C-terminal PfCel-
Tos domain was found to be cleaved off from the fusion 
protein [20].
A one prime/two boost immunization scheme (pro-
tein in adjuvant formulation) of groups of four rabbits 
with four different doses (0.1, 1, 10 and 50 µg) of an equi-
molar mixture of the three recombinant fusion proteins 
(VAMAX 1, 2 and 6), using the human-compatible adju-
vant Alhydrogel®, yielded a low titer (3.8 × 104) for the 
0.1-µg dose, and reasonable titers (5.6 × 105–2.5 × 106) 
for the three higher doses with no differences between 
the 1  and 10  µg doses. This agrees with the results of a 
recent mouse immunization study using 0.01, 0.03, 0.1, 
0.3 and 1  µg doses of PfAMA1_DiCo mix formulated 
in alum (Rehydragel®) which also showed clear dose-
dependent seroconversion (Faber et  al., pers. comm..). 
In contrast, no significant differences in total IgG levels 
were observed for the four different doses, indicating that 
the induced total IgG is adjuvant-dependent rather than 
antigen-dose-dependent in the investigated context.
Specific IgG concentrations were determined for all 
included antigen domains except the Q5A epitope, where 
no reactivity could be shown in ELISA. Even though 
Faber et  al. have demonstrated that fusing smaller anti-
gen domains like PfMSP1_19 to PfAMA1_DiCo could 
improve immune responses against a smaller domain 
that suffers from low immunogenicity when used alone 
[41], Q5A might be too small to sufficiently benefit from 
this effect in the context of the VAMAX6 fusion protein.
For the blood stage it was possible to attribute the 
growth inhibition activity (measured by GIA) exclusively 
to PfAMA1-specific antibodies because the addition of 
an excess of PfAMA1_DiCo mix completely abolished 
parasite growth inhibition in a reversal of growth inhibi-
tion assay. In this context, neither the PfMSP1_19 specific 
antibodies (P1 = 14 µg/ml and P50 = 43 µg/ml PfMSP1-
19 in 10 mg/ml total IgG, respectively) nor any potential 
PfRH5_Q5A-specific antibodies (not determined) con-
tributed to the inhibition of growth. As previously sug-
gested [20], this phenomenon may reflect the presence of 
PfMSP1_19-specific and PfRH5_Q5A-specific antibodies 
that are below the concentration required for the reliable 
determination of growth inhibition in GIAs (>100 µg/ml 
for PfMSP1_19-specific antibodies [41] and >30  µg/ml 
for PfRH5_Q5A-specific antibodies [21]).
To investigate whether the in vitro protective efficacy of 
the induced immune responses is directly proportional to 
the amount of relevant, component-specific IgG, CFCA 
analysis was carried out using the different components 
(PfCSP_TSR, PfAMA1_DiCo mix, PfMSP1_19 and 
Pfs25). The estimated in vitro IC50 values observed for the 
Table 3 Summary of IC50-values
SGM assay Strain P1 P50
3D7
IC50 [mg/ml] Total IgG >10.0 9.95
IC50 [mg/ml] 95 % CI ND 7.625–12.98
IC50 [µg/ml] PfCSP_TSR-specific >4.47 11.92
IC50 [µg/ml] 95 % CI ND 9.130–15.56
GIA Strain P1 P50
3D7A 7G8 V1‑S 3D7A 7G8 V1‑S
IC50 [mg/ml] Total IgG 27.32 31.46 23.55 8.085 8.105 9.36
IC50 [mg/ml] 95 % CI 18.89–39.50 24.45–40.49 17.92–30.94 5.812–11.25 7.120–9.227 7.672–11.420
3D7 7G8 V1-S 3D7 7G8 V1-S
IC50 [µg/ml] PfAMA1_DiCo mix specific 160.0 184.3 137.9 120.3 120.6 139.3
IC50 [µg/ml] 95 % CI 110.6–231.3 143.2–237.1 105.0–181.2 86.49–167.3 106.0–137.2 114.2–169.8
SMFA Strain P1 P50
NF54:HSP70:GFP:luc
IC50 [mg/ml] Total IgG 0.7879 0.1427
IC50 [mg/ml] 95 % CI 0.434–1.43 0.09459–0.2153
IC50 [µg/ml] Pfs25-specific 1.409 1.049
IC50 [µg/ml] 95 % CI 0.6935–2.862 0.6952–1.583
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pre-erythrocytic-stage antigen PfCSP_TSR (12 µg/ml for 
P50), the blood-stage antigen PfAMA1_DiCo mix (120–
140  µg/ml for P50) and the sexual-stage antigen Pfs25 
(1.0  µg/ml for P50) were in the same range as reported 
in other studies featuring or including these antigens in 
comparable assays [13, 20, 29, 42].
The correlation of these antibody concentrations with 
the estimated IC50 values observed in the correspond-
ing stage-specific parasite-inhibition assays confirmed 
the absence of qualitative differences in terms of in vitro 
efficacy between antigen-specific IgG induced by differ-
ent doses of the antigen cocktail, and that the efficacy 
Fig. 5 Confirmation of blood-stage in vitro efficacy measured in growth inhibition assay (GIAs) using three P. falciparum strains. GIAs with asexual P. 
falciparum parasites (strains: 3D7A, 7G8, V1-S) were carried out using purified total rabbit IgG pools from immune serum samples (P1: 1 µg antigen 
dose, blue; P50: 50 µg antigen dose, orange). Each data point represents the mean, including standard deviations of technical triplicates within 
one experiment. a The dose-dependency of GIA was investigated for P1 and P50 using 10, 5, 2.5 and 1.25 mg/ml total IgG. b Reversal of growth 
inhibition was analysed using 10 mg/ml total IgG of P1 and P50 and a serial 1/3 dilution of PfAMA1_DiCo mix (250–0.34 µg/ml) as a competitor, and 
based on these results the inhibition was also correlated with the PfAMA1_DiCo mix-specific antibody concentration (c). Based on both graphs, the 
IC50 values for total IgG as well as PfAMA1_DiCo Mix-specific antibodies were calculated and summarized in Table 3
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in relation to total IgG is only dose-dependent in this 
context. Comparable IC50 values were also obtained 
for hyperimmunization with the predecessor cocktail 
(VAMAX 1, 2 and 4) using a strong lipopolysaccharide-
based formulation (Biogenes proprietary adjuvant) [20], 
which further indicates that maximizing antigen-specific 
titers should be the main focus of further optimization 
efforts, preferentially with higher doses >50  µg, which 
should not be critical, when looking at the antigen doses 
used within approved complex combination vaccines 
such as Infanrix hexa® (GSK). Additionally, the poten-
tial of other human compatible adjuvants like Motanide 
ISA720 and AS02 (as shown for an PfAMA1-FVO-based 
vaccine candidate by Roestenberg et  al.) or combina-
tions thereof to significantly increase antibody responses 
against the VAMAX-mixture could be investigated [28]. 
Furthermore, alternative particulate presentation formats 
like virus-like-particle fusions, currently being evaluated 
in a clinical trial (ClinicalTrials.Gov Id: NCT02013687) 
with the P. falciparum sexual stage antigen Pfs25, would 
open an additional strategy to improve immunogenicity.
The antigen component-specific IgG amounts showed 
an almost linear correlation with the quantitative rep-
resentation of the corresponding component within the 
context of the mixture (Fig. 7), agreeing with the results 
presented in the previous study [20], and further empha-
sizing the potential to explore this correlation for the 
“fine tuning” of stage-specific functionality according 
to the strongly-biased IC50 requirements for parasite 
growth inhibition (at least based on in  vitro efficacy in 
rabbits) in the context of malaria vaccine development. 
Small domains (e.g. PfMSP1-19) and promising inhibi-
tory epitopes (e.g. PfRH_5Q5A) are most likely to require 
multivalent presentation, when used in combination with 
more and/larger antigens (e.g. PfAMA1).
Conclusions
This study demonstrates that the amounts of vaccine-
specific antibodies induced following the immunization 
of rabbits with four different doses (0.1, 1, 10 and 50 µg) 
strongly depend on antigen dose when using a human-
compatible adjuvant (Alhydrogel®) and vaccination 
scheme (one prime/two boosts). A comparison of the 
results with those obtained in an earlier study based on 
a hyper-immunization regime, in which higher levels of 
antigen-specific IgG were observed, suggests that there 
is significant need for improvement to generate a higher 
immune response and match efficacy requirements, 
Fig. 6 Confirmation of the transmission-blocking activity of antibodies induced by VAMAX-Mix immunization by standard membrane feeding assay 
(SMFA). The SMFA was performed with total IgG purified from neutral rabbit serum (NRS, control, white), P1 (1 µg antigen dose, blue) and P50 (50 µg 
antigen dose, orange) at 1, 0.3, 0.1, 0.03 and 0.01 mg/ml, and the mean luminescence intensity values for 24 individual mosquitoes from a single 
experimental feeds are shown (the box indicate the 25th and 75th percentiles whereas the whiskers indicate minimum and maximum luciferase 
values). The transmission-blocking activity is expressed by comparing the mean luciferase activity of P1 and P50 with the corresponding luciferase 
activity in the NRS control group. The dose-dependency of the transmission-blocking activity was used to determine the IC50 values for total IgG as 
well as Pfs25-specific antibodies and the results are summarized in Table 3
Page 13 of 15Boes et al. Malar J  (2016) 15:279 
especially for a PfAMA1-based blood stage vaccine, by 
using higher doses, better adjuvants and/or better formu-
lations. The results also confirm the previously described 
strong positive correlation between antigen-specific anti-
body titers and the quantitative representation of the 
corresponding component within the vaccine mixture, 
suggesting an overrepresentation of smaller antigens or 
peptides e.g. by increasing valency or by formation of 
VLPs would be beneficial.
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Fig. 7 Molecular weight dependency of component-specific reactivity. Y-axis: Relative proportion of specific IgG calculated for the five compo-
nents using the CFCA results of P1 (a) and P50 (b). The sum of individual component-specific IgG concentrations was set to 100 %. X-axis: Relative 
proportion of molecular weight calculated for the five components. The sum of molecular weights of VAMAX 1, VAMAX 2 and VAMAX 6 was set to 
100 %. Reference points: 0/0 % (not depicted) and 100/100 % (red star), PfAMA1_DiCo mix (red), Pfs25 (blue), PfMSP1_19 (orange) and PfCSP_TSR 
(light gray). Each symbol represents the value for each individual rabbit (R1, R2, R3 and R4). The corresponding geometric means are included as 
horizontal black lines. For detailed statistical analysis refer to the “Methods” section
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